Bank of America’s Fortress Biotech FBIO Stock Holding History

Bank of America’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-1,333	Closed	-$140K	–	7956
2013 Q3	$140K	Buy	+1,333	New	+$163K	﹤0.01%	5742

Other funds holding FBIO

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of America's FBIO Position: Q1 2026 in Review

Bank of America sold out of Fortress Biotech (FBIO) in Q1 2026, closing a stake of 459 shares — an estimated $1.68K sold.

Bank of America first reported a position in FBIO in Q2 2013 and held it in 51 quarters. The position peaked at $1.18M in Q3 2013. 51 funds tracked by Wall St. Rank hold FBIO as of Q1 2026.

Bank of America reported no remaining Fortress Biotech position as of Q1 2026 after selling out during the quarter.
Bank of America sold 459 Fortress Biotech shares in Q1 2026, an estimated $1.68K.
Bank of America first reported a position in Fortress Biotech in Q2 2013 and held it in 51 quarters.
Bank of America's Fortress Biotech position peaked at $1.18M in Q3 2013.
51 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.